Literature DB >> 7122634

The pathology of Gaucher disease.

R E Lee.   

Abstract

Several features of Gaucher disease have been described related to an experience gained from a study of 275 patients. These include splenic nodules, a nodular form of cirrhosis affecting the liver of patients who have severe disease as well as unsuspected involvement of the brain. The anatomic distribution of Gaucher cells in the brain may be an age related phenomenon. Various types of involvement of the lungs can produce severe cyanosis or cor pulmonale according to the anatomic distribution of the Gaucher cells. The belief that bone disease can be produced by prior splenectomy was dispelled by a study of 239 patients with type I and type III disease. The reasons for the association of malignant tumors with older patients who have type I disease is not understood but should encourage careful follow-up of these patients. As we enter the second century of our knowledge of this disease we should keep Dr. Gaucher's talent of making careful clinicopathological observations in mind as we search for clues to the better understanding of the various clinical forms of the disease.

Entities:  

Mesh:

Year:  1982        PMID: 7122634

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  32 in total

1.  Gaucher disease gene GBA functions in immune regulation.

Authors:  Jun Liu; Stephanie Halene; Mei Yang; Jameel Iqbal; Ruhua Yang; Wajahat Z Mehal; Wei-Lien Chuang; Dhanpat Jain; Tony Yuen; Li Sun; Mone Zaidi; Pramod K Mistry
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S.

Authors:  Marc N Offman; Marcin Krol; Israel Silman; Joel L Sussman; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

Review 3.  The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism.

Authors:  John DePaolo; Ozlem Goker-Alpan; Ted Samaddar; Grisel Lopez; Ellen Sidransky
Journal:  Mov Disord       Date:  2009-08-15       Impact factor: 10.338

Review 4.  Current issues in enzyme therapy for Gaucher disease.

Authors:  G A Grabowski
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 5.  Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.

Authors:  Hagit N Baris; Ian J Cohen; Pramod K Mistry
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

6.  Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy.

Authors:  Philip Stein; Advitya Malhotra; Andrew Haims; Gregory M Pastores; Pramod K Mistry
Journal:  J Inherit Metab Dis       Date:  2010-08-04       Impact factor: 4.982

Review 7.  Imaging of Gaucher disease.

Authors:  William L Simpson; George Hermann; Manisha Balwani
Journal:  World J Radiol       Date:  2014-09-28

8.  Gaucher disease: resetting the clinical and scientific agenda.

Authors:  Pramod K Mistry; Neal J Weinreb; Roscoe O Brady; Gregory A Grabowski
Journal:  Am J Hematol       Date:  2009-04       Impact factor: 10.047

9.  Apparent diffusion coefficient vale of the brain in patients with Gaucher's disease type II and type III.

Authors:  Ahmed Abdel Khalek Abdel Razek; Nahed Abd El-Gaber; Ahmed Abdalla; Abeer Fathy; Ahmed Azab; Ashraf Abdel Rahman
Journal:  Neuroradiology       Date:  2009-07-15       Impact factor: 2.804

10.  Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model.

Authors:  You-Hai Xu; Ying Sun; Sonya Barnes; Gregory A Grabowski
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.